AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
AIM Vaccine Co., Ltd. has announced the submission of an application for clinical trials of its new absorbed tetanus vaccine, signaling an expansion of its vaccine portfolio and a step towards multi-disease prevention in China. The company is also developing a ‘Tetravaccine’ aimed at reducing infant and young child vaccination frequency, aligning with industry trends towards multi-disease vaccines. These developments are expected to bolster the company’s market position and contribute to the projected growth of China’s multi-disease vaccine market, which is estimated to reach RMB 9.572 billion by 2030.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.
